Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Table 2 Number of reports and reporting odds ratio of BRONJ stratified by formulations and dosages

Dosage form	Drug name		Case	Non-case	Total	Reporting odds ratio	(95 % CI)
Intravenous	Pamidronate		223	171	394	315.0	(256.3 − 387.0)
		30 mg − 45 mg^a	44	59	103	159.4	(107.5 − 236.2)
		90 mg^a	66	48	114	298.0	(204.8 − 433.6)
	Zoledronate		809	972	1,781	346.2	(308.2 − 388.8)
		4 mg^a	494	651	1,145	226.6	(198.8 − 258.3)
Oral	Arendronate (oral)		414	1,252	1,666	92.3	(81.4 − 104.5)
		5 mg^a	155	388	543	91.7	(75.6 − 111.3)
		35 mg^a	202	702	904	68.2	(57.8 − 80.4)
	Risedronate		152	721	873	48.4	(40.3 − 58.0)
		2.5 mg^a	73	374	447	42.5	(32.9 − 54.8)
		17.5 mg^a	35	213	248	34.9	(24.3 − 50.1)

ISSN: 2055-0294